Latest news with #ISCO
USA Today
05-07-2025
- Sport
- USA Today
Field is set for Genesis Scottish Open where 3 golfers will earn spots into British Open
The Genesis Scottish Open is the final prelude to the 2025 Open Championship. While everyone entered in the event at the Renaissance Club in North Berwick, Scotland, wants to claim a PGA Tour title, there are other rewards to be had. The Scottish Open is the final event in the R&A's Open Qualifying Series, which help golfers earn their way into the Open Championship, held this year at Royal Portrush in Northern Ireland. The Genesis Scottish Open will be the final event on the Open Qualifying Series for 2025. According to the R&A: The leading three players, not already exempt, at the Renaissance Club between 10-13 July will earn their place into The 153rd Open, at Royal Portrush the following week. Robert MacIntyre will return as the Scottish Open's defending champion. Other notables in the 156-man field in Scotland include: Ludvig Aberg, Matt Fitzpatrick, Rory McIlroy, Collin Morikawa, Justin Rose, Xander Schauffele, Scottie Scheffler, Adam Scott, J.J. Spaun and Justin Thomas. You can see the full field here: Meanwhile, there is an opposite-field event on the PGA Tour as well, as Hurstbourne Country Club in Louisville will host the ISCO Championship. For the last six years, it was at Keene Trace Golf Club near Lexington was the host golf course for this tournament. Notables in the ISCO include Emiliano Grillo, Adam Hadwin, Miles Russell and Camilo Villegas. The 2024 ISCO champ, Harry Hall, is not defending as he in the Scottish Open field in 2025.
Business Journals
06-05-2025
- Business
- Business Journals
PGA Tour leaders visit Louisville for Derby, talk golf's future
Among those who played at Valhalla Golf Club on Friday were (from left) PGA Tour Commissioner Jay Monahan, ISCO CEO/Valhalla Golf Club Co-Owner Jimmy Kirchdorfer, Diamond Holdings Executive Chair Pat Battle and PGA Tour Chief Communications Officer Tyler Dennis.
Yahoo
31-03-2025
- Business
- Yahoo
International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results
SAN DIEGO, CA / / March 31, 2025 / International Stem Cell Corporation (OTCQB:ISCO) ( ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2024. FY 2024 Financial Highlights: Revenues increased to $9.09 million in 2024, an increase of 17% compared to $7.79 million in 2023. Combined operating income for the year ended December 31, 2024, from our two wholly owned subsidiaries, Lifeline Cell Technology and Lifeline Skin Care, increased to $2.39 million, an increase of 29%, compared to $1.85 million in 2023. Loss from operations decreased to $68,000 for the year ended December 31, 2024, a decrease of 90%, compared to $663,000 in 2023. "2024 has been a successful year for International Stem Cell Corporation, marked by both strong financial performance and continued progress in our clinical trial. Our revenue growth, coupled with a significant reduction in operational losses, underscores the strength of our business model and the demand for our biomedical products. At the same time, we remain committed to advancing our pioneering ISC-hpNSC® program, building upon the promising interim results observed in our Phase 1 clinical trial. Looking ahead, we are focused on leveraging these achievements to drive further growth, accelerate our research, and enhance value for our shareholders," stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ( and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( For more information, please visit or contact: ir@ To subscribe to receive ongoing corporate communications, please click on the following link: To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: and Safe harbor statement Statements pertaining to anticipated developments and company achievements, expected clinical studies (including results and ongoing evaluation of the phase 1 clinical trial), and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements. International Stem Cell Corporation and SubsidiariesConsolidated Balance Sheets(In thousands, except share and par value data) December 31, 2024 2023 Assets Current assets: Cash $ 1,230 $ 1,588 Accounts receivable, net 1,058 574 Inventories 1,149 1,263 Prepaid expenses and other current assets 123 96 Total current assets 3,560 3,521 Non-current inventories 252 266 Property and equipment, net 257 215 Intangible assets, net 721 800 Right-of-use assets 352 557 Deposits and other assets 31 31 Total assets $ 5,173 $ 5,390 Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Deficit Current liabilities: Accounts payable $ 186 $ 364 Accrued liabilities 527 485 Operating lease liabilities, current 330 276 Advances 250 250 Related party note payable 3,395 3,457 Total current liabilities 4,688 4,832 Operating lease liabilities, net of current portion 115 445 Total liabilities 4,803 5,277 Commitments and contingencies (Note 11) Series D redeemable convertible preferred stock, $0.001 par value; 50 shares authorized; 43 shares issued and outstanding; liquidation preference of $4,300 at December 31,2024 and 2023 4,300 4,300 Stockholders' Deficit: Non-redeemable convertible preferred stock, $0.001 par value; 10,004,310 and 10,004,310 shares authorized; 5,254,310 and 5,254,310 shares issued andoutstanding; liquidation preference of $9,811 and $9,796 at December 31, 2024 and 2023, respectively 5 5 Common stock, $0.001 par value; 120,000,000 shares authorized; 8,004,389shares issued and outstanding at December 31, 2024 and 2023 8 8 Additional paid-in capital 106,742 106,276 Accumulated deficit (110,685 ) (110,476 ) Total stockholders' deficit (3,930 ) (4,187 ) Total liabilities, redeemable convertible preferred stock and stockholders' deficit $ 5,173 $ 5,390 International Stem Cell Corporation and SubsidiariesConsolidated Statements of Operations(In thousands, except share and per share data) Year Ended December 31, 2024 2023 Product sales $ 9,085 $ 7,789 Operating expenses: Cost of sales 3,764 3,181 General and administrative 3,516 3,514 Selling and marketing 1,216 1,246 Research and development 657 511 Total operating expenses 9,153 8,452 Loss from operations (68 ) (663 ) Other income (expense): Employee retention credit - 663 Interest expense (145 ) (139 ) Other income, net 4 8 Total other (expense) income, net (141 ) 532 Net loss (209 ) (131 ) Net loss per common share, basic and diluted $ (0.03 ) $ (0.02 ) Weighted-average common shares used to compute net loss per share, basic and diluted 8,004,389 8,004,389 Contacts:International Stem Cell CorporationRussell A. Kern, PhD, Executive VPPhone: 760-940-6383Email: ir@ SOURCE: International Stem Cell Corporation View the original press release on ACCESS Newswire Sign in to access your portfolio
